Table 2. Operative and postoperative data.
| Bioprosthetic valve | Mechanical valve | |||||
|---|---|---|---|---|---|---|
| HD patients (n = 60) | Non-HD patients (n = 152) | P-Value | HD patients (n = 8) | Non-HD patients (n = 18) | P-Value | |
| Bicuspid valveb (%) | 6 (10) | 25 (16) | 0.16 | 2 (25) | 5 (28) | 0.64 |
| Isolated AVR (%) | 26 (43) | 68 (45) | 0.87 | 2 (25) | 7 (39) | 0.41 |
| Concomitant procedure | ||||||
| CABG (%) | 14 (23) | 26 (17) | 0.32 | 3 (38) | 0 (0) | <0.01a |
| Valve (%) | 14 (23) | 26 (17) | 0.30 | 1 (13) | 7 (39) | 0.07 |
| Mitral (%) | 8 (13) | 20 (13) | 1.00 | 1 (13) | 7 (39) | 0.07 |
| Tricuspid (%) | 9 (15) | 12 (8) | 0.41 | 1 (13) | 3 (17) | 0.45 |
| Aorta (%) | 5 (8) | 24 (16) | 0.19 | 2 (25) | 2 (11) | 0.26 |
| Emergency (%) | 5 (8) | 10 (7) | 0.76 | 0 (0) | 3 (17) | 0.31 |
| Prosthetic valve type | ||||||
| CEPd (%) | 21 (35) | 56 (37) | 0.83 | – | – | |
| Magnae (%) | 23 (38) | 61 (40) | 0.87 | – | – | |
| Resilia (%) | 8 (13) | 16 (11) | 0.74 | – | – | |
| Trifecta (%) | 2 (3) | 3 (2) | 0.61 | – | – | |
| Mosaic (%) | 5 (8) | 15 (10) | 0.75 | – | – | |
| Mitroflow (%) | 1 (2) | 0 (0) | 0.44 | – | – | |
| Crown (%) | 0 (0) | 1 (1) | 0.52 | – | – | |
| SJM (%) | – | – | – | 5 (63) | 14 (78) | 0.71 |
| ATS (%) | – | – | – | 0 (0) | 1 (6) | 0.55 |
| On-X (%) | – | – | – | 3 (38) | 3 (17) | 0.16 |
| Prosthetic valve size (mm) | ||||||
| <19 | 16 (27) | 26 (17) | 0.22 | 6 (75) | 11 (61) | 0.84 |
| 21 | 21 (35) | 63 (41) | 0.71 | 2 (25) | 4 (22) | 0.75 |
| 23 | 20 (33) | 46 (30) | 0.75 | 0 | 2 (11) | 0.23 |
| >25 | 3 (5) | 17 (11) | 0.46 | 0 | 1 (6) | 0.12 |
| Average prosthetic valve size (mm) | 21 ± 2 | 22 ± 2 | 0.19 | 19.3 | 20.2 | 0.08 |
| 21 ± 2 | 0.03a | 20 ± 2 | 0.03a | |||
| CPB time (min) | 241.2 | 226.9 | 0.77 | 278.6 | 276.4 | 0.83 |
| Cross-clamp time (min) | 159.7 | 151.0 | 0.85 | 185.3 | 187.7 | 0.49 |
| Postop PPMc (%) | 14 (23) | 41 (27) | 0.72 | 1 (13) | 2 (11) | 0.76 |
| Hospital death (%) | 2 (3) | 2 (1) | 0.13 | 1 (13) | 1 (6) | 0.53 |
| Average follow-up year | 2.7 (0–7.9) | 4.0 (0–10.0) | <0.01a | 3.1 (0–9.7) | 4.1 (0–9.9) | 0.02a |
| Thromboembolic events | 4 | 3 | <0.02a | 0 | 0 | – |
| Major bleeding events | 2 | 2 | 0.28 | 0 | 0 | – |
| Deep sternal wound infection | 1 | 0 | 0.63 | 0 | 0 | – |
Values are mean ± SD or n (%) unless otherwise specified.
aStatistically significant (P <0.05)
bIncluding monocuspid aortic valve
cAll recorded PPM were moderate (0.65 ≤EOAi ≤0.85).
dCarpentier-Edwards Perimount pericardial aortic bioprosthesis
eCarpentier-Edwards Perimount Magna Ease pericardial aortic bioprosthesis
HD: hemodialysis; AVR: aortic valve replacement; CABG: coronary artery bypass grafting; SJM: St. Jude Medical; CPB: cardiopulmonary bypass; PPM: patient–prosthesis mismatch; SD: standard deviation; Postop: postoperative; EOAi: Effective Orifice Area index